5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris

Acne Vulgaris Clinical Trial

Official title:

5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris: A Double-Blind, Placebo Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00714454
• Other study ID #: 97269358-APS
• Status: Completed
• Phase: N/A
• First received: July 3, 2008
• Last updated: July 11, 2008

Study information

• Verified date: July 2008
• Source: University of Miami
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

12-week study to compare the efficacy and safety of a course of a twice daily treatment with APS in the form of a lotion to its vehicle for the treatment of acne.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 39 Years

Eligibility

Inclusion Criteria:

• Subject has read, understood, and signed appropriate informed consent, photo consent, and HIPAA consent in their own language.

• Subject has visible mild to severe acne, as assessed by the investigator.

• Subject will be available and willing to return for follow-up visits.

• Subject agrees not to use any other acne treatment products during the study.

• Subject is otherwise healthy, non-febrile, and is not suffering from an infection likely to require antibiotic therapy during the study period.

• Subject or guardian must be able to understand the new HIPAA regulations and sign the HIPAA form.

• Subject is between the ages of 18 and 39.

• Subject agrees and understands that APS or its vehicle is to be applied to the subject twice daily for 12 weeks; no other topical or systemic medication affecting the course of acne and/or evaluability is to be used during the study.

• Subject agrees to use only the cleanser, moisturizer with sunscreen, and treatment provided by the study site for the duration of the study.

• Subject understands and agrees that he/she can not be treated with a systemic antibiotic for acne during the study.

• Subject agrees he/she will not use an acne topical treatment for two weeks prior to Day 0.

Exclusion Criteria:

• Subject or guardian has not signed informed consent, photo consent or HIPAA form.

• Subject is suffering from a condition likely to require medical attention, including administration of oral or systemic antibiotics, oral or systemic corticosteroids, or any other treatment which in the opinion of the investigator could influence the results of the study.

• Subject is pregnant or lactating.

• Subject is suffering from an abnormal skin condition not usually associated with acne.

• Subject will not be available for follow-up visits.

• Subject has been previously enrolled in any clinical study in which treatment was received within the past 30 days.

• Subjects without comedones, papules, pustules, or nodules.

• Subject has a history of hypersensitivity to any other ingredients of the study lotion.

• Subject has a history of anaphylaxis.

• Subject is not able to avoid excessive sun exposure.

Study Design

N/A

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Other:
• APS Topical Lotion

• Placebo

Locations

Country	Name	City	State
United States	University of Miami Cosmetic Center	Miami Beach	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Miami	Ikeno Clinic

Country where clinical trial is conducted

United States,